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ABSTRACT 
 
 
We investigated activity and mechanism of action of two AhR ligand antitumor agents, 
AFP 464 and 5F 203 on human renal cancer cells, specifically examining their effects on 
cell cycle progression, apoptosis and migration.  
TK-10, SN12C, Caki-1 and ACHN human renal cancer cell lines were treated with AFP 
464 and 5F 203. We evaluated cytotoxicity by MTS assays, cell cycle arrest and apoptosis 
by flow cytometry and corroborated a mechanism of action involving AhR signal 
transduction activation. Changes in migration properties by wound healing assays were 
investigated: 5F 203-sensitive cells show decreased migration after treatment, therefore we 
measured c-Met phosphorylation by Western blot in these cells.  
Both compounds caused cell cycle arrest and apoptosis in sensitive cell lines TK-10, 
SN12C and Caki-1 cell lines. 5F 203 induced a decrease in cell viability which was more 
remarkable marked than AFP 464. This cytotoxicity was reduced after treatment with the 
AhR inhibitor α-NF for both compounds indicating Ahr AhR signaling activation plays a 
role in the mechanism of action. 5F 203 is sequestered by TK-10 cells and induces 
CYP1A1 expression; 5F 203 only potently inhibited migration of TK-10, Caki-1 and 
SN12C cells, and inhibited c-Met receptor phosphorylation in TK-10 cells.  
AhR ligand antitumor agents AFP 464 and 5F 203 represent potential new candidates for 
the treatment of renal cancer. 5F 203 only inhibited migration of sensitive cells and c-Met 
receptor phosphorylation in TK-10 cells. c-Met receptor signal transduction is important in 
migration and metastasis. Therefore we consider that 5F 203 offers potential for the 
treatment of metastatic renal carcinoma. 
 
 
INTRODUCTION 
 
The aryl hydrocarbon receptor (AhR) is a cytosolic transcription factor. After binding with 
its ligand the receptor translocates to the nucleus, binds to xenobiotic response element 
(XRE) promoter sequences, activating target genes including cytochrome P4501A1 
(CYP1A1). Initially, AhR was linked to detoxification functions of cell products and 
environmental pollutants. Our research group has described a new role for the AhR 
signaling pathway as a novel molecular target for cancer therapeutics. Currently, there are 
two antitumor agent AhR ligands, Aminoflavone (AFP 464) and Benzothiazole 
benzothiazole (5F 203), which have been tested clinically (Fig. 1). It has been proved 
proven that Benzothiazole 5F 203 and Aminoflavone AFP 464 are AhR-targeted agents (1, 
2).The Benzothiazole benzothiazole 5F 203 lysylamide prodrug Phortress has been tested in 
phase I clinical trials, and disease stabilization was achieved in 28% patients recruited (3). 
Although neither breast nor ovarian carcinoma patients received Phortress, instabilizing 
disease in 28% patients recruited(3).In  preclinically models, 5F 203 and Phortress evoked 
potent antiproliferative activity in breast and ovarian tumor models, inducing CYP1A1 
expression and generating DNA adducts which are converted to lethal strand breaks in 
sensitive models cell lines and xenografts only (4,5). We have previously described that 5F 
203 induced enhanced AhR nuclear translocation and CYP1A1 expression and AhR 
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nuclear translocation in human breast cancer cells (6), and in the human ovarian cell line 
IGROV‐1. andIn ascites‐isolated ovarian cancer cells, that were sensitive sensitivity to 5F 
203 correlated with cytosolic AhR translocation to nuclei, upon treatment of ovarian cancer 
cells ex vivo. 5F 203 possessed antiproliferative/pro‐apoptotic activity inducing oxidative 
stress measured as ROS formation, JNK, ERK, and P38MAPK phosphorylation, DNA 
damage and cell cycle arrest prior to apoptosis. In contrast, 5F 203 failed to induce 
CYP1A1 expression, AhR translocation or oxidative stress in 5F 203‐resistant SKOV‐3 
cells (7). 
AlsoInterestingly, preclinical NCI 60 cell line panel data showed that TK10 cells are were 
consistently sensitive to benzothiazoles 4F 5F 203 and Phortress. Intriguingly, Phortres 
stabilized disease in the two renal carcinoma patients recruited to trial (in 1 patient stability 
was maintained for 16 cycles). Therefore, we in this work study we intended tosought to 
examine the AhR pathway activation and CYP1A1 inducibility in TK10 and other renal 
carcinoma cell lines after treatment with 5F 203. Given the poor prognosis associated with 
kidney cancer and the paucity of therapeutic options, preclinical investigations of the use of 
aminophenyl benzothiazole experimental antitumour agents against these tumours are 
warranted.  
 
Figure 1: AFP 464 and 5F 203 chemical structures 
 
Aminoflavone (AF; NSC 686288, AFP 464, NSC710464) is a new anticancer agent 
undergoing phase II clinical evaluation. It has demonstrated antiproliferative effects in 
MCF-7 human breast cancer cells mediated by AhR. AF also exhibits noteworthy evidence 
of antitumor activity in vitro and in vivo against neoplastic cells of renal origin. AF 
treatment of sensitive renal cells, in contrast to resistant cells, promoted the induction of 
CYP1A1, the covalent binding of AF-reactive intermediates and apoptosis (8). AF 
treatment also induced apoptosis, in human renal cancer sensitive cells e.g. TK-10, Caki-1 
and SN12C, which was not observed in ACHN resistant cells. AF induced time-dependent 
AhR nuclear translocation and AhR transcriptional activity in sensitive renal cancer cell 
lines. A renal cell strain derived from a human papillary tumor also showed sensitivity to 
AF, as well as AhR pathway activation and drug-induced apoptosis. AhR translocation was 
proposed as a marker of sensitivity to AF in sensitive renal tumor cells of different 
histological origin, for clinical trials (9). Much focus has been emphasized on the vascular 
endothelial growth factor (VEGFR), platelet derived growth factor, and PI3K pathways, 
leading to the development, and Food and Drug Administration (FDA)-approval of 
multiple targeted agents for RCC (10). As these drugs generally slow the progression of 
disease with only modest objective responses, it is necessary to identify new molecular 
targets in RCC for the development of more effective therapeutic strategies. Dysregulation 
of c-Met and its ligand, hepatocyte growth factor (HGF), have been implicated in tumor 
development, invasion, and angiogenesis in malignancies. Mutations in the c-Met gene 
have been identified in papillary RCC (11). It has been shown that loss of von Hippel–
Lindau (VHL) expression and hypoxia lead to upregulation of c-Met expression in clear 
cell RCC. Studies performed in clear cell lines demonstrated that c-Met protein was 
activated in renal cancer cell lines, and cell proliferation was blocked by SU11274 
(sunitinib) and ARQ 197(11). 
Kidney cancer rapidly acquires resistance to antiangiogenic agents such as 
Sunitinibsunitinib, developing an aggressive migratory phenotype (facilitated by c-Met 
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signal transduction).  The aim of this study was to investigate the action of AFP464, the 
Aminoflavone aminoflavone pro-drug currently used in clinical trials, and 5F 203 on renal 
cancer cells specifically examining their effects on cell cycle progression, apoptosis and 
cell migration. Both compounds caused cell cycle arrest and apoptosis but only 5F 203 
potently inhibited migration of TK-10, Caki-1 and SN12C cells and inhibit athe migration 
involved signal transduction pathwaycascade, such asinvolving c-Met receptor signaling, in 
TK-10 cells.  
 
 
 
MATERIALS AND METHODS 
 
Cell Lines 
The following human renal cancer cell lines were obtained from the National Cancer 
Institute (NCI) repository: TK-10, SN12C, Caki-1 and ACHN. They were cultured in 25 
cm2 T flasks with 5% CO2 in RPMI medium (Gibco) supplemented with 10% fetal bovine 
serum (FBS; PAA). 
 
 
Antiproliferative activity 
Renal cell lines grown in 25 cm2 flasks were removed by trypsinization and seeded into 96-
well culture dishes at a concentration of 750 cells per well. Cells were allowed to grow for 
48 h at 37˚C in a humidified atmosphere containing 5% CO2.  
 
- AFP464 treatment: Cells were treated with AFP464: 10 nM, 100 nM, 500 nM and 1 µM 
or dextrose water (control) for an additional 120 h. 
- 5F 203 treatment: Cells were treated with 5F 203; 100 nM, 500 nM, 1 µM, 10 µM and 
100 µM or DMSO (0.1%) (control) for an additional 120 h. 
 
In both cases cell viability was determined by the MTS method (Promega). To study AhR 
pathway involvement, cells were pre-incubated for 1 h with AhR specific antagonist α-
naphthoflavone (α-NF, 1 μM). 
 
Cell cycle progression: 
Cells were seeded into 6-well culture dishes at a concentration of 3 x 105 cells per well. 
After 24-48 h, cells were treated with test agents. 
- AFP 464: Control (dextrose water); α-NF (1 µM); AFP464 (1 µM) for 24 and 48 h; pre-
incubation for 1 h with α-NF (1 µM) followed by α-NF (1 µM) + AFP464 (1 µM) for 24 
and 48 h. 
- 5F 203: Control (DMSO 0.1%); α-NF (1 µM); 5F 203 (1 µM) for 24 and 48 h; pre-
incubation for 1 h with α-NF (1 µM) followed by α-NF (1 µM) + 5F 203 (1 µM) for 24 and 
48 h. 
Thereafter, cells were harvested, washed in PBS, and fixed in 70% ethanol. DNA was 
stained by incubating cells in PBS containing propidium iodide; fluorescence was measured 
and analyzed using Cyflogic software version 1.2.1. The analysis of the DNA analyses 
allowed us to determinate the cell distribution in each cell cycle phase. 
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Detection of 5F 203 in nutrient medium: 
TK-10 cells were seeded into 25 mL flasks and allowed 24 h to adhere and begin mitoses. 
Medium was changed and 5F 203 introduced at a final concentration of 100 nM. Media, 
collected from flasks at time zero,  and4 h, 24 h, 48 h and 72 h thereafter, were mixed with 
3-fold volumes of HPLC-grade acetonitrile. Protein was precipitated by centrifugation at 14 
000 rpm for 10 min. and supernatants analyzed by HPLC. The analytical system consisted 
of a Hewlett-Packard1050 series module (solvent delivery pump, autosampler, and multiple 
wavelength detector) and a Hewlett-Packard 1046A fluorescence detector. 5F 203 
separation was effected at room temperature on a C18 reversed-phase column (150 x 4.6 
mm i.d.) using a mobile phase of 65% methanol and 35% H2O, delivered at a flow rate of 1 
mlmL/min. 5F 203 eluted at 338 nm; was identified with UV detection and with 
fluorescence detection (excitation344 nm; emission 434 nm) and confirmed by 
chromatographic analysis of authentic 5F 203. 
 
Wound Healing: 
To analyze the effect of AFP464 or 5F 203 on migration, cells were seeded in 6-well plates 
and incubated for 48 h so as to achieve an 80-90% confluent monolayer. Cells were treated 
for 24 h with 10-4 µM to 1µM AFP 464 or 5F 203. After this time had elapsed, a single 
scratch wound was created in the monolayer with a tip and then immediately photographed 
at time 0 or Tf(approximately 18 h later, depending on each cell line). Cell migration was 
assessed by determining the covered area at T0 and Tf with the program ImageJ and then 
the percentage migration was calculated using the following equation: (Tf*100)/T0. We 
considered 20 fields per plate. Migration percentage was analyzed with the program 
GraphPad Prism5. Wounds were photographed, with aimaged under a phase contrast phase 
microscope. 
 
 
Western blot: 
Cells were seeded in dishes (100×20 mm) at a density of 1-2 x 106 per dish, allowed 24 h to 
attach, before being exposed to benzothiazoles5F 203 (1 μM, 5 min, 10 min, 30 min, 1 h, 4 
h or 24 h). Following exposure, cell lysates were prepared and protein concentrations 
evaluated by Bradford assay (12). Proteins (50 µg per simple) were separated by PAGE. 
CYP 1A1, c-Met, phosphorylated c-Met and GAPDH 1o Abs were purchased from Cell 
Signaling Technologies. 2o Abs were obtained from Dako. Densitometric analyses of 
Western blots were performed using Image J.  
 
 
RESULTS 
 
AFP464 and 5F 203 induce cytotoxicity in human renal cancer cell lines 
 
In this study, we measured the sensitivity of cells to AFP464 as an in vitro regression 
(shown by a decrease in cell metabolism measured by the MTS assay). 
The incubation of TK-10, SN12C and Caki-1 cells with 1 μM AFP464 for 5 days induced a 
significant decrease in cell viability (compared to control viability, considered to be 100%: 
TK-10, 21,.22±10,.9%; SN12C, 50,.91±4,.9%; Caki-1, 87,.24±9,.1% cells; Figure 2, with 
respect to the control which wasconsidered 100%). The eEffects was were dependent on 
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drug concentration. In contrast, ACHN cells were not sensitive to AFP464 as significant 
growth inhibition was not observed at any drug concentration (Fig. 2Ai). In order to 
investigate whether the sensitivity of renal cancer cells to AFP 464 is mediated by AhR 
activation, we pre-incubated the cells with the AhR specific inhibitor, α-NF (1 μM), for 1 h 
prior to treatment with 1 μM AFP464 plus α-NF. The AhR inhibitor significantly reduced 
the cytotoxic effects of AFP 464 in TK-10 and partially reduced the cytotoxic effects in 
SN12C with respect to control (Fig.2Aii). 
 
Figure 2: AFP and 5F 203 effect on cellular viability 
A) i- Cells were incubated with AFP464 or dextrose water for 5 days. ii- Cells were 
incubated with AFP 464 (1 M) for 5 days alone or pre-treated for 1 h with -NF (1 
M) and then treated with AFP 464 (1 M) plus -NF (1 M) for 5 days. Cellular 
viability was assessed by MTS assay. The values represent the average of three 
independent experiments, * p < 0.05 with respect to control cells. 
B) i- Cells were incubated with 5F 203 or DMSO (0.1%) for 5 days. ii- Cells were 
incubated with 5F 203 (1 M) for 5 days alone or pre-treated for 1 h with -NF (1 
M) and then treated with 5F 203 (1 M) plus -NF (1 M) for 5 days. Cellular 
viability was assessed by MTS assay. The values represent the average of three 
independent experiments,* p < 0.05 with respect to control cells. 
 
 
In addition, sensitivity of TK-10, SN12C and Caki-1 cells to 5F 203 was also measured. 
Interestingly, incubation of these cell lines with 0.1 µM 5F 203 for five 5 days induced a 
decrease dose-dependently decreased in cell viability, which was more remarkable 
remarkably than did AFP464 (survival was calculated as TK-10, 45±10%; SN12C, 26±3%; 
Caki-1, 36±3%, with respect to the control which was considered 100%) , which was 
maintained with increased concentrations (Fig.2Bi). As with AFP464, the cell line ACHN 
did not show sensitivity to 5F 203. Involvement of the AhR pathway was also assessed by 
using the AhR specific inhibitor (α-NF; 1 μM)); results show that the cytotoxic effects 
obtained withof 5F 203 was were significantly reduced diminished in TK-10 and SN12C 
cells by α-NF-mediated inhibition of AhR with respect to the controlsignal transduction.  
 
AFP464 and 5F 203 cause altered cell cycle distribution and apoptosis in sensitive 
renal cancer cells 
 
As previous results indicate that AFP464 (NSC710404) induced DNA damage and 
apoptosis in renal cancer cells (9) and 5F 203 causes evoked DNA damage in breast and 
ovarian cancer cells, we investigated perturbations in the cell cycle after treatment of renal 
cells with AFP464 and 5F 203. For this approach, cells were exposed to 1 µM AFP464 ,or 
1 µM 5F 203 or 0.1% DMSO for 24 and 48 h and subsequently processed for cell cycle 
analyses. As illustrated (Fig. 3A), AFP464 only caused an increase in phase G0/G1 in TK-
10 cells at 24 h (56.7 ± 0.15% control; 61.65 ± 1.65% at 24 h). However, significant 
accumulation of sub‐G0 events was detected in TK-10 cells from 2.5 ± 0.6 % (control) to 
8.13 ± 0.2% at 48 h, in SN12C cells 6.2 ± 0.7 % (control) to 17.64 ± 0.9 % at 48 h, and 
Caki-1 from 2.44 ± 0.2 % (control) to 6.05 ± 1% at 48 h. In contrast, ACHN cell cycle was 
not perturbed following treatment with AFP464. 
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Figure 3: AFP464 and 5F 203 altered cell cycle distribution.  
A) The effect of 1 μM AFP464 effecton cell cycle distribution: Cells were harvested, 
washed with PBS and fixed in 70% ethanol, then stained with propidium iodide and 
analyzed by flow cytometry. The figure shows graphs for TK10, SN12-C, Caki-1 
and ACHN cells.  
B) The effect of 1 μM 5F 203 on cell cycle distribution5F 203 effect: Cells were 
harvested, washed with PBS and fixed in 70% ethanol, then stained with propidium 
iodide and analyzed by flow cytometry. The figure shows graphs for TK10, SN12-
C, Caki-1 and ACHN cells.  
In both cases, a one representative experiment, out of three, is shown;.  20 000 events were 
analyzed. The values represent the average of three independent experiments *, p < 0.05; 
**, p < 0.01 with respect to control cells. 
 
5F 203 caused an increase in phase G0/G1 in SN12C and Caki-1 cells. While this effect 
was observed at 24 h in SN12C cells (control: 54.8 ± 0.62 % vs 24 h: 73.48 ± 5.44 %), in 
Caki-1 cells G0/G1 arrest was seen at 24 and 48 h (control: 52.05 ± 0.47 %, 24 h: 61.9 ± 
3.9 %, 48 h: 64.34 ± 2.03 %).  Accumulation of Sub-G0 events was observed in TK-10, 
SN12C and Caki-1 cells at both assayed times. TK-10 cells: from 4.15 ± 2.13 (control) to 
6.4 ± 2.4 % and 11.0 ± 4.0 (24 and 48 h, respectively); SN12C cells: from 0.76 ± 0.64 % to 
4.6 ±1.4 % and 11.1 ± 0.4 % (24 and 48 h, respectively); Caki-1 cells: from 2.4 ± 0.22 % to 
4.2 ± 1.09 % and 4.6 ± 1.6 % (24 and 48 h, respectively). In contrast, ACHN cell cycle was 
not perturbed following treatment with 1 µM 5F 203 (Fig. 3B). 
 
 
5F 203 is depleted from medium of TK-10 cells and induces expression of CYP1A1. 
 
It has previously been reported that 5F 203 is stable in medium (13). When added to TK-10 
cancer cell nutrient medium(100 nM 5F 203) , 5F 203 was rapidly depleted (Figure 4A). 
After 24 h 60% depletion was noted after treatment of cells with 100 nM 5F 203; after 72 
h treatment, medium levels of 5F 203 were below detection levels.  
 
Figure 4: 5F 203 depletion from nutrient medium and CYP1A1 induction 
A) Time-dependent depletion of 5F 203 from nutrient medium of TK-10 cells exposed 
to 100 nM 5F 203.  
B) Induction of CYP1A1 protein expression following exposure (24 h, 1 μmM) of TK-
10 cells to fluorinated analogues of 2-(4-amino-3methylphenyl)benzothiazole, 
including 5F 203* 
 
Potent cytosolic AhR ligands, aminophenylbenzothiazoles (including 5F 203) have also 
been reported to activate AhR signaling, thereby and induce inducing expression of 
CYP1A1 (13-15). In lysates of TK-10 cells exposed to fluorinated 2-(4-amino-3-
methylphenyl)benzothiazole analogues including 5F 203 (1μM; 24 h) CYP1A1 protein 
could be detected (Figure 4B). 
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Impact of AFP464 and 5F 203 treatment on cell migration 
 
We investigated the effect of AFP464 and 5F 203 treatments on migration of renal tumor 
cells in vitro. As shown in Fig. 5, AFP464 treatment decreased migration neither in the 
sensitive nor in the resistant cell lines (61 ± 8 %, 62 ± 1 %, and 64 ± 7 % of migration 
percentage for TK-10, SN12C and ACHN respectively as compared to 70 ± 5 %, 67 ± 15 % 
and 73 ± 8 % of in the controls). 
 
Figure 5: AFP464 and 5F 203 effects on cellular migration. 
A) AFP464 wound healing assay: TK10, SN12C and ACHN cells were incubated with 
AFP464 for 24 h with the dilutions shown described in the methodology. After that, 
the A wound was made with a yellow tip;, measuring the initial and final wound 
areas were measured (Tf= 20 h post wound) and analayzed with the program Image 
J program. The graph shows the migration percentage migration for each dilution 
realized. Values that are significantly different from controls were are indicated by 
*p< 0.05. Representative fields of from one experiment are shown under each 
graph. Experiments were performed in triplicate. (Andrea confirm) 
B) 5F 203 wound healing assay: TK10, SN12C, Caki-1 and ACHN cells were 
incubated with 5F 203 for 24 h with the dilutions shown described in the 
methodology.  A wound was made with a yellow tip; the initial and final wound 
areas were measured (Tf= 14 h post wound) and analayzed with the Image J 
program. The graph shows the percentage migration for each dilution realized. 
Values that are significantly different from controls are indicated *p< 0.05. 
Representative fields from one experiment are shown under each graph. 
Experiments were performed in triplicate (Andrea confirm)After that, the wound 
was made with a yellow tip, measuring the initial and final area (Tf= 14 hpost 
wound) with the program ImageJ. The graph shows the migration percentage for 
each dilution realized. Values that are significant different were indicated by *p< 
0.05. Representative fields of one experiment are shown under each graph. Andrea, 
I don’t know what happened to A), B) – please ignore the cross out, it is the 
autoformatting! 
In contrast, 5F 203  (1 M) significantly decreasedsuppressed cell migration in the three 
sensitive cell lines, 42 ± 6 %, 18 ± 7 % and 29 ± 2 % in TK-10, SN12C and Caki-1 cell 
lines respectively as compared to 69 ± 1 %, 63 ± 3 % and 62 ± 4 % for controls. For the 
non-sensitive cell line (ACHN), migration percentage was of 46 ± 2 %, as compared to 38 
± 1 % for control. While in TK-10 and Caki-1 cells, treatment decreased migration with 10-
1 µM and 1 µM 5F 203 decreased migrationrespectively, inhibition of SN12C cells` 
migration inhibition iswas apparent at all concentrations examined (≥10-4μM). 
 
 
 
Effect of 5F 203 on c-Met phosphorylation in TK-10 cells 
 
As treatment with 5F 203 demonstrated inhibition of TK-10 cells `migration, and p-Met is 
involved in the migration process, cell lysates were subjected to p-Met Western blot 
analyses. TK-10 cells were exposed to 1 μM 5F 203 for 5 min, 10 min, 30 min, 1 h, 4 h or 
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24 h. We observed time dependent significant down regulation from 5 min to 1 h where 1 h 
examined. Particularly significant down-regulation of phosphor C-Met was detected in 
lysates of TK10 cells exposed to 1 μM 5F 203 for 1 h (P<.001; Fig. 6). 
 
Figure 6: 5F 203 effect on c-Met phosphorylation 
 
 A) Western blots illustrating total and phosphorylated c-Met expression in lysates of 
TK-10 cells treated with 1 μM 5F 203 for 5 min, 10 min, 30 min, 1 h, 4 h or 24 h. 
Total c-Met 10Ab recognizes c-Met (145 KDa) and phospho c-Met 145 KDa. 
Representative phospho c-Met blots are shown (n=3). Lysates were prepared on 3 
separate occasions; 1 representative total c-Met and GAPDH (loading control) blots 
are shown.  
a) B) Densitometry was performed on all blots to quantify c-Met and phosphorylated 
c-Met expression. The values represent the average of three independent 
experiments. * p< 0.05;** p < 0.01 and *** p < 0.001 with respect to control cells. 
 
 
DISCUSSION 
 
Our previous studies showed that renal cancer cell lines of human origin, such as Caki-1, 
TK-10 and A498, and human renal cell strains lines derived from patients with renal tumors 
were very sensitive to AF (2). However, other cell lines and cell strains were classified as 
resistant. Treatment with AF of sensitive cells resulted in AhR signaling pathway activation 
which leads to CYP1A1 induction, inducing AF metabolism to reactive intermediates that 
cause DNA damage and apoptosis, measured by cytokeratin 18 cleavage. In our previous 
report, we indicated that papillary renal tumors were more sensitive to AF than clear cell 
tumors (8). The enhanced activity of AF against the papillary variant of renal cell 
carcinoma is of special value. Except for Temsirolimus and Sunitinib, there are little or no 
data regarding the safety and efficacy of new targeted drugs in papillary histology renal 
tumors and there is a need for the development of new effective therapies (16). 
We suggested that the AhR may represent a new molecular target for the treatment of these 
tumors, distinct from proteins currently targeted in the clinic. AhR translocation and 
activation may be used as a biomarker in tumor biopsies to predict sensitivity to treatment 
with AF of renal tumors of different histological types. This could be incorporated into 
phase II clinical trials, together with other markers of sensitivity, such as the induction of 
CYP1A1, high covalent binding of metabolites and apoptosis, for the selection of patients 
that potentially could respond to the treatment with this agent (8, 9). 
Our studies showed that in sensitive cells AF induced formation of apoptotic bodies, ;  
incubation with the AhR inhibitor, α-NF, prior to treatment with AF, decreased the number 
of apoptotic bodies formed (9). Indicating that the AF-induced apoptosis is mediated 
by AhR activation. Also, we previously studied the molecular pathway involved in AF-
induced apoptosis, and we observed the induction of p-P53 and P21 levels after treatment 
with1 μM AF in these cells between 3 and 6 h, which confirms that this compound caused 
apoptosis and presumably cell cycle arrest (9). This finding is consistent with the induction 
of p-P53 and P21 that was previously reported after AF treatment of MCF-7 breast cancer 
cells (17). In addition, caspase 3 activation and consequent PARP cleavage after treatment 
with AF in TK-10 cells was found which is consistent with the DNA damage and apoptosis 
 10 
 
caused by this antitumor agent. Furthermore, caspase 3-dependent apoptotic body 
formation was observed in MCF-7 breast cancer cells after treatment (18), which is 
consistent with our observation in renal cancer cells. Since AFP464 is a prodrug 
administered to patients which is metabolized to form AF, we assumed that apoptosis via p-
P53 and P21 and caspase activation also occurred in our system.  
In this paper we demonstrated accumulation of TK-10, SN12C and Caki-1 events in Sub-
G0 after treatment of cells with AFP464 which indicates apoptosis caused by this clinical 
used Aminoflavone aminoflavone derivative.  
Our current data confirm that AFP464 caused cytotoxicity in sensitive human renal cancer 
cells which was significantly reduced when we pretreated with the AhR inhibitor α-NF, 
indicating AhR activation (Fig 2). We confirmed that in sensitive renal cells AFP464 
induces translocation of AhR to the nucleus, indicating AhR signaling activation;, and in 
addition, Histone histone H2AX phosphorylation which indicates indicated DNA damage 
caused by the drug (data not shown; 19). 
When we studied cell cycle arrest we observed AFP464 only caused an increase in phase 
G0/G1 in TK-10 cells at 24 h.  
Finally we demonstrated that AFP464 did not change migration properties of renal cancer 
cells.  
The Novel data have been generated following treatment of cell lines of renal carcinoma 
origin obtained with AhR ligand 5F 203 are novel.  TK-10, SN12C and Caki-1 were 
sensitive to 5F 203, whereas ACHN represents a resistant cell line.  
Interestingly, incubation of these cell lines with 0.1 µM 5F 203 for five 5 days induced 
decreased a decrease in cell viability which was more remarkable than AFP 464. This 
cytotoxicity was reduced after treatment of cells with the AhR inhibitor α-NF. 
Antitumorbenzothiazoles such as 5F 203 are potent AhR ligands (20); activity has been 
shown to be mediated via AhR signal transduction in mammary carcinoma cells, with 
subsequent induction of CYP1A1 and biotransformation of 5F 203 to cytotoxic nitrenium 
species (21). Here we demonstrate that this pathway is activated in sensitive renal cell 
carcinoma lines. Moreover, we demonstrate depletion of 5F 203 from nutrient medium of 
TK-10 cells and induction of CYP1A1 protein expression (Fig 4). 
Apoptosis, detected as accumulation of sub‐G0 events was also detected after treatment 
with 5F 203 in the three sensitive cell lines. 5F 203 caused an increase in phase G0/G1 in 
SN12C and Caki-1 cells only. Arrest in G1 phase was observed also after treatment of 
ovarian sensitive cells with 5F 203 (7).  
In contrast to AFP464, 5F 203 significantly decreased cell migration in the three sensitive 
cell lines. A decrease in wound healing ability was observed in sensitive cell lines after 24 
h treatment with concentrations of 5F 203, compared to the control. Also the 
mostConsistent with loss of migratory potential, asignificant decrease in c-Met 
phosphorylation was observed at 1 h in TK-10 cells treated with 1 µM 5F 203. Inhibition of 
c-Met activity by 5F 203 is consistent with previous observations: 5F 203 (1 µM; 24 h) 
decreased c-Met phosphorylation by 85% and 69 % in MCF-7 and MDA-MB-435 breast 
carcinoma cells respectively ?????.(unpublished data).It was proposed We speculate that 5F 
203, a potent AhR ligand triggers activation of a signaling cascade which potentially 
inhibits HIF signal transduction and hence c-Met transcription and subsequent activation 
(22). The Met signaling pathway is a key pathway for the treatment of renal cancer (11) and 
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is also involved in metastasis progression; therefore we consider that 5F 203 has potential 
for the treatment of renal metastatic carcinoma. 
Andrea, instead of (or as well as) plotting the ration between total and phosphoMet in the 
bar grapg, do you think you could plot total Met:GAPDH ration and phosphoMet:GAPDH 
ratio please? It does look as though total Met levels  are down regulated – as would make 
sense according to our speculative hypothesis:  5F 203-triggered AhR signal transduction 
activation would reduce HIF-1β levels available, therefore inhibit HIF signaling, therefore 
c-Met transcriotion and expression – but depending on its half-life, lysates may need to be 
prepared > 24 h. 
All that said, it has been shown 5F 203 also inhibits phospho c-Met – as you say a good 
target in renal carcinoma. 
AhR was predominantly expressed in the nuclei of high-grade clear cell RCC (ccRCC) and tumor-
infiltrating lymphocytes (TILs), and its expression levels in cancer cells and TILs correlated with the 
pathological tumor stage and histological grade. A multivariate Cox analysis revealed that the 
strong expression of AhR in cancer cells was a significant and independent predictor of disease-
specific survival. AhR ligands up-regulated the expression of AhR and CYPs and promoted invasion 
by up-regulating MMPs. Furthermore, siRNA for AhR down-regulated CYPs, and inhibited cancer 
cell invasion together with the down-regulation of MMPs. These results suggest that AhR regulates 
the invasion of ccRCC and may be involved in tumor immunity. Therefore, inhibiting the activation 
of AhR may represent a potentially attractive therapeutic target for ccRCC patients. 
Enhanced activation of AhR in renal cancer linked with poor prognosis. It was suggested that 
inhibition of AhR would be therapeutically beneficial. (Activation of aryl hydrocarbon receptor 
promotes invasion of clear cell renal cell carcinoma and is associated with poor prognosis and 
cigarette smoke. 
Ishida M1,2, Mikami S3, Shinojima T1, Kosaka T1, Mizuno R1, Kikuchi E1, Miyajima A1, Okada Y4, Oya 
M1.) 
 
 
YResults section, page 7: 5F 203 is depleted from medium of TK-10 cells and induces expression of 
CP1A1. That is the relevance of these findings. Are they also tractable in other renal carcinoma 
lines? Did you try in other renal cell lines? Yes, I`ll find these data. 
Attached – for DF 203 3 renal cells line TK10, Caki-1, A498; for 4F 203, 
just TK10. 
|The authors provided data that inhibition of AhR by alpha-NF may impact proliferation inhibition 
by both compounds (effect of single alpha-NF treatment on proliferation. We have this 
control Figure 2). This statement has to be taken with care as they did not include essential 
controls on the 
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CONCLUSSIONS 
 
AhR ligand antitumor agents, such as AFP 464 and 5F 203, represent potential new 
candidates for the treatment of renal cancer. Both compounds caused cell cycle arrest and 
apoptosis. 5F 203 is sequestered by TK-10 cells and induces CYP1A1 expression; 5F 203 
only potently inhibited migration of TK-10, Caki-1 and SN12C cells, and inhibited c-Met 
receptor phosphorylation, in TK-10 cells. C-Met receptor signal transduction promotes 
migration and metastasis. 
Therefore we consider that 5F 203 offers potential for the treatment of metastatic renal 
carcinoma. 
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